TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Alaunos Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.13+0.50 (+19.01%)
Close on Oct 19, 2026
- Market cap
- $7.61M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-84500.0%
Net margin
-83520.0%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -50.0% | -88.0% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -3282.0% | -73.0% | -198.1% | |
| Return on assets | -127.1% | -62.6% | -146.0% | |
| Current ratio | 6.63 | 7.11 | 2.45 | |
| Debt to equity | – | 0.00 | – | |
| Interest coverage | – | – | – | |
| Capex to revenue | 8.0% | – | 1960.0% | |
| Diluted shares | 1M | 1M | 2M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Alaunos Therapeutics generated $128.68M from operations and spent $3.88M on capital expenditure, dividends and share buybacks. 99% of that went back into the business.
Generated
$128.68M
Used
$3.88M
Capital expenditure$3.83M99%Dividends$00%Share buybacks$45.00K1%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-83520.0%
×Asset turnover0.00×
×Equity multiplier1.36×
=Return on equity, FY2025-198.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -83520.0% | 0.00× | 1.36× | -198.1% |
| FY2024 | -46790.0% | 0.00× | 1.32× | -111.8% |
| FY2023 | -93580.0% | 0.00× | 1.63× | -20.9% |
| FY2022 | -1291.2% | 0.04× | 1.65× | -78.1% |
| FY2021 | -19786.7% | 0.00× | 1.33× | -86.5% |
| FY2018 | -36381.5% | 0.00× | -17.85× | 945.0% |
| FY2017 | -341.7% | 0.15× | -1.22× | 62.4% |
| FY2016 | -2409.2% | 0.05× | 25.82× | -3282.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$4.18M
- Cash generatingOperating cash flow above zero-$2.87M
- Return on assets improvedROA up on the prior year-56.6% → -151.6%
- Earnings backed by cashOperating cash flow above net income-$2.87M vs -$4.18M
- Less leverageLong-term debt to assets fell0.0% → –
- Better liquidityCurrent ratio rose3.98 → 2.45
- No dilutionShare count did not rise2M → 2M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00